Liver Transplantation and Coronavirus Disease 2019 (COVID-19)
NCT ID: NCT04695756
Last Updated: 2021-01-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
1000 participants
OBSERVATIONAL
2020-12-15
2021-07-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The indirect impact of the COVID-19 pandemic on the access to the medical care of patients on the waiting list for organ transplantation might be multifactorial, including the need to relocate health-related resources (medical personnel, supplies, critical care unit beds, etc), the risk of COVID-19 transmission among donors or patients on the waiting list, and also after transplantation. Additionally, the pandemic reduces significantly the donor pool.
We consider that it is important to assess the impact that the pandemic has in particular individual populations, such as in patients requiring a liver transplant. Along with the lockdown, the rate of organ donation has dropped, and liver transplant programs across the world have reduced or suspended their activity. Unfortunately, this is invariably associated with an increase in mortality on the waiting list.
Knowing the impact of the pandemic on patients who require a liver transplant will provide tools to understand and plan the health resources related to the care of these patients, not only at present but also in the following years.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
COVID-19 in Liver Transplant Recipients
NCT04361591
COVID-19 Pandemic and Worldwide Organ Procurement
NCT04416256
Covid Vaccination in Liver Transplantation
NCT05079165
Assessment of the Impact of COVID-19 on Transplant Patients and on Patients Awaiting Transplantation
NCT04376775
Multicenter CTS Pre-and Post-Transplantation Covid-19 Serum Studies
NCT04694573
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The indirect impact of the COVID-19 pandemic on the access to the medical care of patients on the waiting list for organ transplantation might be multifactorial, including the need to relocate health-related resources (medical personnel, supplies, critical care unit beds, etc), the risk of COVID-19 transmission among donors or patients on the waiting list, and also after transplantation. Additionally, the pandemic reduces significantly the donor pool.
We consider that it is important to assess the impact that the pandemic has in particular individual populations, such as in patients requiring a liver transplant. Along with the lockdown, the rate of organ donation has dropped, and liver transplant programs across the world have reduced or suspended their activity. Unfortunately, this is invariably associated with an increase in mortality on the waiting list.
Knowing the impact of the pandemic on patients who require a liver transplant will provide tools to understand and plan the health resources related to the care of these patients, not only at present but also in the following years.
The primary objectives of the study will be
To Compare the following outcomes in patients requiring liver transplantation during the epidemiological weeks of COVID-19 pandemic in Argentina and the same weeks of 2019 according to national data registry of procurement and transplantation:
1. Number of patients registered on the liver transplant waiting list
2. Number of deaths on the liver transplant waiting list
3. Number of liver transplants
For this purpose, we will carry out a time series analyses using the national data registry of procurement and transplantation database. The effect of both periods will be analysed as time interrupted series, which is a quasi-experimental design. The following two periods will be compared as segments of the interrupted time series:
* Baseline period (Period not exposed to the pandemic represented by the same epidemiological weeks of 2019 )
* Pandemic period COVID-19. (Period between the epidemiological weeks of 2020 affected by the pandemic declared by the WHO from 11/March/2020)
The unit of analysis will be the epidemiological weeks, and the study population will be all Argentinian over 17 years of age. Regarding patients who require liver transplantation, those who registered for isolated liver transplantation in the National Procurement and Transplant Institute will be included.
A Poisson regression model will be used to assess the association between the period and the incidence of the events of interest. ARIMA models will be used following the 4 steps proposed by Box and Jenkings
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
ECOLOGIC_OR_COMMUNITY
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
People who require liver transplant
We will compare the year before the beginning of the COVID-19 Pandemia with the period during the COVID-19 Pandemia.
COVID-19 pandemic
The exposure of this observational study is the COVID-19 pandemic
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
COVID-19 pandemic
The exposure of this observational study is the COVID-19 pandemic
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Argentinean
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Agency for Scientific and Technological Promotion, Argentina
OTHER
Hospital Italiano de Buenos Aires
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Diego Hernan Giunta, PhD, MPH, MD
Coordinator of the non-sponsored area of the departemt of Research
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sebastián Marciano, MS, Msc
Role: STUDY_CHAIR
Hospital Italiano de Buenos Aires
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital Italiano de Buenos Aires
Buenos Aires, , Argentina
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1405
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.